Strategies for University Hospitals
Partnering with Big Medtech
University hospitals have long struggled with their relationship with Big Medtech and Big Pharma. Here we interview Neil Wright, commercial director at Guys and St Thomas NHS Foundation Trust who has thought long and hard about this. We also cover these complex partnering issues at our annual conference on June 19. And please fill in our survey on your strategic priorities.
Here we interview Neil Wright, commercial director at Guys and St Thomas NHS Foundation Trust who has thought long and hard about these issues. But we’ve seen similar approaches at Erasmus in the Netherlands and in Denmark.
The new model does away with the idea of a passive customer receiving new products or of companies sponsoring individual professors. Instead, it is based on managers working to identify areas where physicians know that new technology will have a real impact. This means that medtech garners insights into where technology can best add value. But all of this calls for long-term relationships and a willingness for medtech to look beyond quarterly sales targets.
Our Strategies for University Hospitals continues the partnering theme at our annual conference on June 19 in London. Scaling up for the Genetics and Data Revolution focuses on how university hospitals and research institutes can best develop the big data platforms they need to implement comprehensive genetic testing and population health management. These are two huge imperatives which they need to address over the next 2-5 years. To succeed calls for a blend of partnership skills, cultural change and long-term planning. These are the themes we discuss at the Forum. Please join us. University hospitals and research institutes can join us for just £250 for the day.
And finally, please take five minutes to complete our survey on your strategic priorities. In exchange, we will send you free of charge our full findings enabling you to swiftly compare your view with those of your peers internationally.
We would welcome your thoughts on this story. Email your views to Max Hotopf or call 0207 183 3779.
